Liver Resection After Selective Internal Radiation Therapy with Yttrium-90 is Safe and Feasible: A Bi-institutional Analysis

Annals of Surgical Oncology

Volumn 24, Issue 4, 2017, Pages 906-913

  Wright, G Paul ^a   Marsh, J Wallis ^a   Varma, Manish K ^b   Doherty, Michael G ^b   Bartlett, David L ^a   Chung, Mathew H ^c,d  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Advanced Radiology Services PC   (United States)

^c SPECTRUM HEALTH   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICROSPHERE; YTTRIUM 90; RADIOPHARMACEUTICAL AGENT; YTTRIUM;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CARCINOMA; EYE MELANOMA; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MIDDLE AGED; MORTALITY RATE; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PEROPERATIVE COMPLICATION; RETROSPECTIVE STUDY; SEGMENTECTOMY; SURVIVAL TIME; ADENOCARCINOMA; ARTIFICIAL EMBOLIZATION; BRACHYTHERAPY; CLINICAL TRIAL; COLORECTAL TUMOR; DIAGNOSTIC IMAGING; EYE TUMOR; LENGTH OF STAY; LIVER TUMOR; MELANOMA; MULTICENTER STUDY; PATHOLOGY; POSTOPERATIVE COMPLICATION; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SECONDARY; X-RAY COMPUTED TOMOGRAPHY;

ADENOCARCINOMA; ADULT; AGED; BRACHYTHERAPY; CARCINOMA, HEPATOCELLULAR; COLORECTAL NEOPLASMS; EMBOLIZATION, THERAPEUTIC; EYE NEOPLASMS; HEPATECTOMY; HUMANS; LENGTH OF STAY; LIVER NEOPLASMS; MELANOMA; MIDDLE AGED; NEUROENDOCRINE TUMORS; PATIENT READMISSION; POSTOPERATIVE COMPLICATIONS; RADIOPHARMACEUTICALS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; YTTRIUM RADIOISOTOPES;

EID: 84996588055     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-016-5697-y     Document Type: Article

References (18)

1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.
2. Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010;304:2154–60.
3. Quan D, Gallinger S, Nhan C, et al. The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: a systematic review. Surgery. 2012;151:860–70.
4. Evrard S, Rivoire M, Arnaud JP, et al. Unresectable colorectal cancer liver metastases treated by intraoperative radiofrequency ablation with or without resection. Br J Surg. 2012;99:558–65.
5. Cauchy F, Aussilhou B, Dokmak S, et al. Reappraisal of the risks and benefits of major liver resection in patients with initially unresectable colorectal liver metastases. Ann Surg. 2012;256:746–52.
6. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497–507.
7. Choi GH, Shim JH, Kim MJ, et al. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology. 2013:269:603–11.
8. Gates VL, Atassi B, Lewandowski RJ, et al. Radioembolization with yttrium-90 microspheres: review of an emerging treatment for liver tumors. Future Oncol. 2007;3:73–81.
9. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52–64.
10. Saxena A, Bester L, Shan L, et al. A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases. J Cancer Res Clin Oncol. 2014;140:537–47.
11. Gaba RC, Lewandowski RJ, Kulik LM, et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol. 2009;16:1587–96.
12. Henry LR, Hostetter RB, Ressler B, et al. Liver resection for metastatic disease after Y90 radioembolization: a case series with long-term follow-up. Ann Surg Oncol. 2015;22:467–74.
13. Rayar M, Sulpice L, Edeline J, et al. Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment. Ann Surg Oncol. 2015;22:3102–8.
14. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
15. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
16. Rahbari NN, Garden OJ, Padbury R, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011;149:713–24.
17. Wang LM, Jani AR, Hill EJ, Sharma RA. Anatomical basis and histopathological changes resulting from selective internal radiotherapy for liver metastases. J Clin Pathol. 2013;66:205–11.
18. Teo JY, Goh BK. Contralateral liver lobe hypertrophy after unilobar Y90 radioembolization: an alternative to portal vein embolization. World J Gastroenterol. 2015;21:3170–3.